Anthony Guy Marson

List of Publications by Year
in descending order

366 papers	17,674 citations	24978 57 h-index	19690 117 g-index
391 all docs	391 docs citations	391 times ranked	19634 citing authors

#	Article	IF	Citations
1	De novo mutations in epileptic encephalopathies. Nature, 2013, 501, 217-221.	13.7	1,351
2	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	6.0	1,085
3	The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet, The, 2007, 369, 1000-1015.	6.3	873
4	The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet, The, 2007, 369, 1016-1026.	6.3	850
5	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. New England Journal of Medicine, 2011, 364, 1134-1143.	13.9	815
6	Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine, 2002, 21, 3337-3351.	0.8	482
7	De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies. American Journal of Human Genetics, 2014, 95, 360-370.	2.6	388
8	Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet, The, 2005, 365, 2007-2013.	6.3	369
9	Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nature Communications, 2018, 9, 5269.	5.8	331
10	The New Antiepileptic Drugs: A Systematic Review of Their Efficacy and Tolerability. Epilepsia, 1997, 38, 859-880.	2.6	326
11	Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2014, 13, 893-903.	4.9	264
12	When to start antiepileptic drug treatment and with what evidence?. Epilepsia, 2008, 49, 3-6.	2.6	262
13	Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurology, The, 2006, 5, 317-322.	4.9	253
14	De Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of Epileptic Encephalopathies. American Journal of Human Genetics, 2016, 99, 287-298.	2.6	247
15	Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. American Journal of Human Genetics, 2019, 105, 267-282.	2.6	237
16	Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia, 2015, 56, 1006-1019.	2.6	212
17	Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurology, The, 2017, 16, 135-143.	4.9	190
18	Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis. Lancet Neurology, The, 2017, 16, 523-531.	4.9	184

#	Article	IF	Citations
19	Patients with epilepsy: Cognitively compromised before the start of antiepileptic drug treatment?. Epilepsia, 2010, 51, 48-56.	2.6	157
20	Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Statistics in Medicine, 2005, 24, 1307-1319.	0.8	141
21	HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review. Clinical Pharmacology and Therapeutics, 2012, 92, 757-765.	2.3	137
22	Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. The Cochrane Library, 2020, 2020, CD010236.	1.5	136
23	Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. The Cochrane Library, 2017, 2017, CD010224.	1.5	135
24	Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review. Epilepsia, 2010, 51, 2423-2431.	2.6	123
25	Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology, 2007, 68, 1188-1196.	1.5	105
26	Thalamotemporal alteration and postoperative seizures in temporal lobe epilepsy. Annals of Neurology, 2015, 77, 760-774.	2.8	104
27	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1375-1386.	6.3	104
28	KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1138-1147.	0.9	103
29	Effect of topiramate on acid–base balance: extent, mechanism and effects. British Journal of Clinical Pharmacology, 2009, 68, 655-661.	1.1	99
30	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1363-1374.	6.3	93
31	Multiple treatment comparisons in epilepsy monotherapy trials. Trials, 2007, 8, 34.	0.7	92
32	Adverse antiepileptic drug effects in new-onset seizures. Neurology, 2011, 76, 273-279.	1.5	91
33	Polygenic burden in focal and generalized epilepsies. Brain, 2019, 142, 3473-3481.	3.7	90
34	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 2017, 127, 2118-2132.	3.9	90
35	The Modified Ketogenic Diet in Adults with Glioblastoma: An Evaluation of Feasibility and Deliverability within the National Health Service. Nutrition and Cancer, 2018, 70, 643-649.	0.9	89
36	Consensus guidelines into the management of epilepsy in adults with an intellectual disability. Journal of Intellectual Disability Research, 2009, 53, 687-694.	1.2	88

#	Article	IF	Citations
37	Vagus nerve stimulation for partial seizures. The Cochrane Library, 2015, , CD002896.	1.5	88
38	Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Research, 2001, 46, 259-270.	0.8	87
39	Describing the genetic architecture of epilepsy through heritability analysis. Brain, 2014, 137, 2680-2689.	3.7	87
40	A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technology Assessment, 2007, 11, iii-iv, ix-x, 1-134.	1.3	87
41	Carbamazepine versus Valproate Monotherapy for Epilepsy: A Meta-analysis. Epilepsia, 2002, 43, 505-513.	2.6	79
42	Measuring patient experience: a systematic review to evaluate psychometric properties of patient reported experience measures (PREMs) for emergency care service provision. International Journal for Quality in Health Care, 2017, 29, 314-326.	0.9	79
43	Current drug treatment of epilepsy in adults. Lancet Neurology, The, 2004, 3, 729-735.	4.9	76
44	Spectral Analysis of Electroencephalography in Premature Newborn Infants: Normal Ranges. Pediatric Research, 2005, 57, 336-341.	1.1	74
45	Relationship Between Blood Pressure, Cerebral Electrical Activity, Cerebral Fractional Oxygen Extraction, and Peripheral Blood Flow in Very Low Birth Weight Newborn Infants. Pediatric Research, 2006, 59, 314-319.	1.1	71
46	Personalized medicine approaches in epilepsy. Journal of Internal Medicine, 2015, 277, 218-234.	2.7	71
47	The modified ketogenic diet for adults with refractory epilepsy: An evaluation of a set up service. Seizure: the Journal of the British Epilepsy Association, 2017, 52, 1-6.	0.9	71
48	An association between type 1 diabetes and idiopathic generalized epilepsy. Annals of Neurology, 2006, 59, 204-206.	2.8	70
49	Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. The Cochrane Library, 2017, 2017, CD011412.	1.5	70
50	Joint modelling of longitudinal and competing risks data. Statistics in Medicine, 2008, 27, 6426-6438.	0.8	69
51	Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurology, The, 2006, 5, 668-676.	4.9	68
52	Rare coding variants in genes encoding GABAA receptors in genetic generalised epilepsies: an exome-based case-control study. Lancet Neurology, The, 2018, 17, 699-708.	4.9	67
53	Exploring changes over time and characteristics associated with data retrieval across individual participant data meta-analyses: systematic review. BMJ: British Medical Journal, 2017, 357, j1390.	2.4	66
54	National Audit of Seizure management in Hospitals (NASH): results of the national audit of adult epilepsy in the UK. BMJ Open, 2015, 5, e007325-e007325.	0.8	62

#	Article	IF	Citations
55	Treatment outcome after failure of a first antiepileptic drug. Neurology, 2014, 83, 552-560.	1.5	61
56	Effect of carbon dioxide on background cerebral electrical activity and fractional oxygen extraction in very low birth weight infants just after birth. Pediatric Research, 2005, 58, 579-585.	1.1	60
57	Carbamazepine versus valproate monotherapy for epilepsy. The Cochrane Library, 2000, , CD001030.	1.5	59
58	Selfâ€reported and parentâ€reported quality of life of children and adolescents with newâ€onset epilepsy. Epilepsia, 2011, 52, 1489-1498.	2.6	59
59	The adverse effects profile of levetiracetam in epilepsy: a more detailed look. International Journal of Neuroscience, 2014, 124, 627-634.	0.8	59
60	Antiepileptic drugs as prophylaxis for post-craniotomy seizures. The Cochrane Library, 2015, , CD007286.	1.5	59
61	Copy number variant analysis from exome data in 349 patients with epileptic encephalopathy. Annals of Neurology, 2015, 78, 323-328.	2.8	59
62	Costâ€effectiveness of screening for <i><scp>HLA</scp>â€<scp>A</scp>*31:01</i> prior to initiation of carbamazepine in epilepsy. Epilepsia, 2015, 56, 556-563.	2.6	59
63	Deep brain and cortical stimulation for epilepsy. The Cochrane Library, 2017, 2017, CD008497.	1.5	59
64	Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurology, The, 2012, 11, 331-340.	4.9	58
65	How Easy are Randomized Controlled Trials in Epilepsy to Find on Medline? The Sensitivity and Precision of Two Medline Searches. Epilepsia, 1996, 37, 377-380.	2.6	56
66	Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. The Cochrane Library, 2012, , CD001901.	1.5	55
67	Risk of recurrence after a first seizure and implications for driving: further analysis of the Multicentre study of early Epilepsy and Single Seizures. BMJ: British Medical Journal, 2010, 341, c6477-c6477.	2.4	54
68	Carbamazepineâ€and oxcarbazepineâ€induced hyponatremia in people with epilepsy. Epilepsia, 2017, 58, 1227-1233.	2.6	54
69	Neuropsychological Outcomes in Randomized Controlled Trials of Antiepileptic Drugs: A Systematic Review of Methodology and Reporting Standards. Epilepsia, 1998, 39, 1088-1097.	2.6	53
70	Factors predictive of resilience and vulnerability in new-onset epilepsy. Epilepsia, 2011, 52, 610-618.	2.6	52
71	The development of a QALY measure for epilepsy: NEWQOL-6D. Epilepsy and Behavior, 2012, 24, 36-43.	0.9	52
72	Shared Genetic Risk Factors Across Carbamazepineâ€Induced Hypersensitivity Reactions. Clinical Pharmacology and Therapeutics, 2019, 106, 1028-1036.	2.3	52

#	Article	IF	Citations
73	The Relationship between Cardiac Output, Cerebral Electrical Activity, Cerebral Fractional Oxygen Extraction and Peripheral Blood Flow in Premature Newborn Infants. Pediatric Research, 2006, 60, 456-460.	1.1	51
74	Antidepressants for people with epilepsy and depression. The Cochrane Library, 2014, , CD010682.	1.5	51
75	Metabolic acidosis with topiramate and zonisamide. Pharmacogenetics and Genomics, 2011, 21, 297-302.	0.7	49
76	Seizure recurrence after antiepileptic drug withdrawal and the implications for driving: further results from the MRC Antiepileptic Drug Withdrawal Study and a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1328-1333.	0.9	48
77	Psychological and behavioural treatments for adults with non-epileptic attack disorder. The Cochrane Library, 2014, , CD006370.	1.5	48
78	Quality-of-Life and Behavioral Outcome Measures in Randomized Controlled Trials of Antiepileptic Drugs: A Systematic Review of Methodology and Reporting Standards. Epilepsia, 2000, 41, 1357-1363.	2.6	47
79	A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 117-122.	0.9	47
80	Epilepsy subtype-specific copy number burden observed in a genome-wide study of 17â€‰458 subjects. Brain, 2020, 143, 2106-2118.	3.7	47
81	Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. BMC Neurology, 2016, 16, 149.	0.8	46
82	Individual participant data metaâ€analysis of intervention studies with timeâ€toâ€event outcomes: A review of the methodology and an applied example. Research Synthesis Methods, 2020, 11, 148-168.	4.2	46
83	Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. , 2005, , CD003032.		45
84	Identifying the biological pathways underlying human focal epilepsy: from complexity to coherence to centrality. Human Molecular Genetics, 2015, 24, 4306-4316.	1.4	45
85	An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes. Journal of Evaluation in Clinical Practice, 2005, 11, 468-478.	0.9	44
86	Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. The Cochrane Library, 2017, 6, CD011412.	1.5	44
87	Maternal Use of Antiepileptic Agents During Pregnancy and Major Congenital Malformations in Children. JAMA - Journal of the American Medical Association, 2017, 318, 1700.	3.8	44
88	Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. Journal of Evaluation in Clinical Practice, 2000, 6, 205-214.	0.9	43
89	Genetic variation in <i>CFH</i> predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology, 2018, 90, e332-e341.	1.5	43
90	Ketogenic diets as an adjuvant therapy for glioblastoma (KEATING): a randomized, mixed methods, feasibility study. Journal of Neuro-Oncology, 2020, 147, 213-227.	1.4	42

#	Article	IF	Citations
91	Time to 12-month remission and treatment failure for generalised and unclassified epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 603-610.	0.9	41
92	A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology, 2006, 66, 1310-1317.	1.5	40
93	Reporting and analysis of open-label extension studies of anti-epileptic drugs. Epilepsy Research, 2008, 81, 24-29.	0.8	40
94	Labor market participation following onset of seizures and early epilepsy: Findings from a UK cohort. Epilepsia, 2009, 50, 1030-1039.	2.6	38
95	Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Research, 2011, 97, 20-29.	0.8	37
96	Identifying new antiepileptic drugs through genomics-based drug repurposing. Human Molecular Genetics, 2017, 26, ddw410.	1.4	37
97	Clinical Administration of New Antiepileptic Drugs: An Overview of Safety and Efficacy. Epilepsia, 1996, 37, S17-22.	2.6	36
98	Exploring the genomic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery. Human Molecular Genetics, 2011, 20, 4381-4394.	1.4	36
99	Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP). The Cochrane Library, 2020, 2020, CD011792.	1.5	36
100	Pregabalin add-on for drug-resistant partial epilepsy. , 2014, , CD005612.		35
101	Sub-genic intolerance, ClinVar, and the epilepsies: A whole-exome sequencing study of 29,165 individuals. American Journal of Human Genetics, 2021, 108, 965-982.	2.6	35
102	Dilemmas in the interpretation of diagnostic accuracy studies on presurgical workup for epilepsy surgery. Epilepsia, 2012, 53, 1294-1302.	2.6	34
103	Which outcomes should we measure in adult epilepsy trials? The views of people with epilepsy and informal carers. Epilepsy and Behavior, 2016, 59, 105-110.	0.9	34
104	Epilepsy and psychosis: a practical approach. Practical Neurology, 2018, 18, 106-114.	0.5	34
105	Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open, 2019, 4, 420-430.	1.3	34
106	Functional analysis of epilepsy‐associated variants in STXBP1/Munc18‐1 using humanized <i>Caenorhabditis elegans</i>. Epilepsia, 2020, 61, 810-821.	2.6	34
107	Topiramate add-on for drug-resistant partial epilepsy. The Cochrane Library, 2014, , CD001417.	1.5	33
108	A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy. Human Molecular Genetics, 2014, 23, 247-258.	1.4	33

#	Article	IF	Citations
109	Antiepileptic drugs as prophylaxis for post-craniotomy seizures. , 2013, , CD007286.		32
110	A comprehensive neuropsychological description of cognition in drug-refractory juvenile myoclonic epilepsy. Epilepsy and Behavior, 2014, 36, 124-129.	0.9	31
111	Pharmacological interventions for epilepsy in people with intellectual disabilities. The Cochrane Library, 2015, , CD005399.	1.5	31
112	Relationship of clinical and quality of life trajectories following the onset of seizures: Findings from the UK MESS Study. Epilepsia, 2011, 52, 965-974.	2.6	30
113	Oxcarbazepine versus phenytoin monotherapy for epilepsy. The Cochrane Library, 2013, , CD003615.	1.5	30
114	Deep brain and cortical stimulation for epilepsy. , 2014, , CD008497.		30
115	Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. , 2001, , CD001769.		29
116	Zonisamide add-on for drug-resistant partial epilepsy. , 2005, , CD001416.		29
117	Executive functions and psychiatric symptoms in drug-refractory juvenile myoclonic epilepsy. Epilepsy and Behavior, 2014, 35, 72-77.	0.9	29
118	Epilepsy and adverse quality of life in surgically resected meningioma. Acta Neurologica Scandinavica, 2017, 136, 246-253.	1.0	29
119	Gabapentin add-on for drug-resistant partial epilepsy. , 1999, , CD001415.		28
120	Lamotrigine add-on for drug-resistant partial epilepsy. , 2001, , CD001909.		28
121	Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery. British Journal of Clinical Pharmacology, 2015, 80, 1149-1159.	1.1	28
122	Qualityâ€ofâ€life outcomes of initiating treatment with standard and newer antiepileptic drugs in adults with newâ€onset epilepsy: Findings from the <scp>SANAD</scp> trial. Epilepsia, 2015, 56, 460-472.	2.6	28
123	Cognitive and behavioural assessments in clinical trials: what type of measure?. Epilepsy Research, 2001, 45, 163-167.	0.8	27
124	Routine anticonvulsants for treating cerebral malaria. The Cochrane Library, 2002, , CD002152.	1.5	27
125	Carbamazepine versus phenobarbitone monotherapy for epilepsy. , 2003, , CD001904.		27
126	Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP). The Cochrane Library, 2016, 7, CD011792.	1.5	27

#	Article	IF	Citations
127	Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2018, 2018, CD001031.	1.5	27
128	Lamotrigine versus carbamazepine monotherapy for epilepsy. , 2006, , CD001031.		26
129	Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. The Cochrane Library, 2013, , CD002217.	1.5	26
130	Zonisamide add-on for drug-resistant partial epilepsy. The Cochrane Library, 2013, , CD001416.	1.5	26
131	Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. , 2013, , CD001769.		26
132	A systematic review of placeboâ€controlled trials of topiramate: How useful is a multipleâ€indications review for evaluating the adverse events of an antiepileptic drug?. Epilepsia, 2015, 56, 1910-1920.	2.6	26
133	Lamotrigine add-on for drug-resistant partial epilepsy. The Cochrane Library, 2016, , CD001909.	1.5	26
134	Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia, 2017, 58, 1734-1741.	2.6	26
135	Outcomes Reported After Surgery for Cauda Equina Syndrome. Spine, 2018, 43, E1005-E1013.	1.0	26
136	Interpreting regulatory trials in epilepsy. Current Opinion in Neurology, 2009, 22, 167-173.	1.8	25
137	Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controlled trial and economic evaluation. Lancet Rheumatology, The, 2021, 3, e347-e356.	2.2	25
138	Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. , 2001, , CD001901.		24
139	Carbamazepine versus phenytoin monotherapy for epilepsy. , 2002, , CD001911.		24
140	Vigabatrin for refractory partial epilepsy. The Cochrane Library, 2013, , CD007302.	1.5	24
141	Gabapentin add-on for drug-resistant partial epilepsy. The Cochrane Library, 2013, , CD001415.	1.5	24
142	Does the concept of resilience contribute to understanding good quality of life in the context of epilepsy?. Epilepsy and Behavior, 2016, 56, 153-164.	0.9	24
143	Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2017, 2, CD001911.	1.5	24
144	Bell's palsy. Western Journal of Medicine, 2000, 173, 266-268.	0.3	24

#	Article	IF	Citations
145	Qualitative study of paramedics' experiences of managing seizures: a national perspective from England. BMJ Open, 2016, 6, e014022.	0.8	23
146	Epilepsy and Pregnancy: For healthy pregnancies and happy outcomes. Suggestions for service improvements from the Multispecialty UK Epilepsy Mortality Group. Seizure: the Journal of the British Epilepsy Association, 2017, 50, 67-72.	0.9	23
147	Comparing Generic and Condition-Specific Preference-Based Measures in Epilepsy: EQ-5D-3L and NEWQOL-6D. Value in Health, 2017, 20, 687-693.	0.1	23
148	Identification of patients who will not achieve seizure remission within 5 years on AEDs. Neurology, 2018, 91, e2035-e2044.	1.5	23
149	New drug treatments for epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 143-147.	0.9	22
150	Topiramate add-on for drug-resistant partial epilepsy. , 2008, , CD001417.		22
151	Exploring loss and replacement of loss for understanding the impacts of epilepsy onset: A qualitative investigation. Epilepsy and Behavior, 2014, 33, 59-68.	0.9	22
152	Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from Epoxide Metabolites of Carbamazepine in Patients. Chemical Research in Toxicology, 2017, 30, 1419-1435.	1.7	22
153	Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia, 2020, 61, 657-666.	2.6	22
154	The role of ketogenic diets in the therapeutic management of adult and paediatric gliomas: a systematic review. CNS Oncology, 2018, 7, CNS17.	1.2	21
155	The prescribable drugs with efficacy in experimental epilepsies (<scp>PDE</scp>3) database for drug repurposing research in epilepsy. Epilepsia, 2018, 59, 492-501.	2.6	21
156	Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. Pharmacogenomics, 2020, 21, 325-335.	0.6	21
157	Withholding the choice of sodium valproate to young women with generalised epilepsy: Are we causing more harm than good?. Seizure: the Journal of the British Epilepsy Association, 2015, 24, 127-130.	0.9	20
158	Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. The Cochrane Library, 2016, , CD007144.	1.5	20
159	Genetic regulation of gene expression in the epileptic human hippocampus. Human Molecular Genetics, 2017, 26, 1759-1769.	1.4	20
160	Patientâ€Focused Drug Development Methods for Benefitâ€"Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs. Clinical Pharmacology and Therapeutics, 2019, 105, 672-683.	2.3	20
161	Probabilistic mapping of thalamic nuclei and thalamocortical functional connectivity in idiopathic generalised epilepsy. Human Brain Mapping, 2021, 42, 5648-5664.	1.9	20
162	Oxcarbazepine versus phenytoin monotherapy for epilepsy. , 2006, , CD003615.		19

#	Article	IF	Citations
163	Vigabatrin for refractory partial epilepsy. , 2008, , CD007302.		19
164	Understanding routine antiepileptic drug decisions: A qualitative analysis of patients' accounts of hospital consultations. Epilepsy and Behavior, 2009, 14, 210-214.	0.9	19
165	Epileptic Seizures in Alzheimer's Disease: Another Fine MESS?. Journal of Alzheimer's Disease, 2011, 25, 417-419.	1.2	19
166	Should we stop saying "epileptic"? A comparison of the effect of the terms "epileptic" and "person with epilepsy". Epilepsy and Behavior, 2016, 59, 21-27.	0.9	19
167	NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in adults with newly diagnosed epilepsy. Epilepsy and Behavior, 2016, 54, 117-127.	0.9	19
168	'Epileptic', 'epileptic person' or 'person with epilepsy'? Bringing quantitative and qualitative evidence on the views of UK patients and carers to the terminology debate. Epilepsy and Behavior, 2017, 67, 20-27.	0.9	19
169	Antiepileptic drugs as prophylaxis for postcraniotomy seizures. The Cochrane Library, 2018, 5, CD007286.	1.5	19
170	Choosing a First Drug Treatment for Epilepsy after SANAD: Randomized Controlled Trials, Systematic Reviews, Guidelines and Treating Patients.. Epilepsia, 2007, 48, 1259-1263.	2.6	18
171	Overwhelming heterogeneity in systematic reviews of observational anti-epileptic studies. Epilepsy Research, 2008, 80, 201-212.	0.8	18
172	Tiagabine add-on for drug-resistant partial epilepsy. The Cochrane Library, 2014, , CD001908.	1.5	18
173	Opening research sites in multicentre clinical trials within the UK: a detailed analysis of delays. BMJ Open, 2014, 4, e005874-e005874.	0.8	18
174	Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. , 2003, , CD002217.		17
175	Open label extension studies and patient selection biases. Journal of Evaluation in Clinical Practice, 2008, 14, 141-144.	0.9	17
176	Pregabalin add-on for drug-resistant partial epilepsy. , 2008, , CD005612.		17
177	When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy. Practical Neurology, 2010, 10, 208-218.	0.5	17
178	'Seizure First Aid Training' for people with epilepsy who attend emergency departments, and their family and friends: study protocol for intervention development and a pilot randomised controlled trial. BMJ Open, 2015, 5, e009040.	0.8	17
179	Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation. CNS Drugs, 2016, 30, 1011-1017.	2.7	17
180	Resource implications of preparing individual participant data from a clinical trial to share with external researchers. Trials, 2017, 18, 319.	0.7	17

#	Article	IF	Citations
181	A Caenorhabditis elegans assay of seizure-like activity optimised for identifying antiepileptic drugs and their mechanisms of action. Journal of Neuroscience Methods, 2018, 309, 132-142.	1.3	17
182	Brivaracetam add-on therapy for drug-resistant epilepsy. The Cochrane Library, 2019, 2019, CD011501.	1.5	17
183	Resting‐state functional brain networks in adults with a new diagnosis of focal epilepsy. Brain and Behavior, 2019, 9, e01168.	1.0	17
184	Breakthrough seizures—Further analysis of the Standard versus New Antiepileptic Drugs (SANAD) study. PLoS ONE, 2017, 12, e0190035.	1.1	17
185	High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study. Epilepsia, 2022, 63, e1.	2.6	17
186	Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. The Cochrane Library, 2022, 2022, CD011412.	1.5	17
187	The association between polymorphisms in <i>RLIP76</i> and drug response in epilepsy. Pharmacogenomics, 2007, 8, 1715-1722.	0.6	16
188	Clobazam as an add-on in the management of refractory epilepsy. The Cochrane Library, 2008, , CD004154.	1.5	16
189	External Validation of a Prognostic Model for Seizure Recurrence Following a First Unprovoked Seizure and Implications for Driving. PLoS ONE, 2014, 9, e99063.	1.1	16
190	The added clinical and economic value of diagnostic testing for epilepsy surgery. Epilepsy Research, 2014, 108, 775-781.	0.8	16
191	Lacosamide add-on therapy for partial epilepsy. The Cochrane Library, 2015, , CD008841.	1.5	16
192	Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2018, 2018, CD001769.	1.5	16
193	Comparison of manual and automated fiber quantification tractography in patients with temporal lobe epilepsy. NeuroImage: Clinical, 2019, 24, 102024.	1.4	16
194	Assessing the role of rare genetic variants in drug‐resistant, non‐lesional focal epilepsy. Annals of Clinical and Translational Neurology, 2021, 8, 1376-1387.	1.7	16
195	Tiagabine add-on for drug-resistant partial epilepsy. , 2002, , CD001908.		15
196	Non-pharmacological interventions for epilepsy in people with intellectual disabilities. , 2007, , CD005502.		15
197	Pharmacological interventions for epilepsy in people with intellectual disabilities. , 2007, , CD005399.		15
198	Validation of a multigenic model to predict seizure control in newly treated epilepsy. Epilepsy Research, 2014, 108, 1797-1805.	0.8	15

#	Article	IF	Citations
199	Pharmacotherapy of focal epilepsy. Expert Opinion on Pharmacotherapy, 2014, 15, 1543-1551.	0.9	15
200	Referral patterns after a seizure admission in an English region: an opportunity for effective intervention? An observational study of routine hospital data. BMJ Open, 2016, 6, e010100.	0.8	15
201	Using routinely recorded data in the UK to assess outcomes in a randomised controlled trial: The Trials of Access. Trials, 2017, 18, 389.	0.7	15
202	Model-based sensitivity analysis for outcome reporting bias in the meta analysis of benefit and harm outcomes. Statistical Methods in Medical Research, 2019, 28, 889-903.	0.7	15
203	Altered structural connectome in non-lesional newly diagnosed focal epilepsy: Relation to pharmacoresistance. NeuroImage: Clinical, 2021, 29, 102564.	1.4	15
204	The impact of epilepsy on the quality of life of patients with meningioma: A systematic review. British Journal of Neurosurgery, 2016, 30, 23-28.	0.4	14
205	Epilepsy management in older people: Lessons from National Audit of Seizure management in Hospitals (NASH). Seizure: the Journal of the British Epilepsy Association, 2017, 50, 33-37.	0.9	14
206	Risk of a seizure recurrence after a breakthrough seizure and the implications for driving: further analysis of the standard versus new antiepileptic drugs (SANAD) randomised controlled trial. BMJ Open, 2017, 7, e015868.	0.8	14
207	A voxel€based asymmetry study of the relationship between hemispheric asymmetry and language dominance in Wada tested patients. Human Brain Mapping, 2018, 39, 3032-3045.	1.9	14
208	Pharmacological management of post-traumatic seizures in adults: current practice patterns in the UK and the Republic of Ireland. Acta Neurochirurgica, 2019, 161, 457-464.	0.9	14
209	Lamotrigine add-on therapy for drug-resistant focal epilepsy. The Cochrane Library, 2020, 2020, CD001909.	1.5	14
210	Topiramate add-on therapy for drug-resistant focal epilepsy. The Cochrane Library, 2019, 2019, CD001417.	1.5	14
211	Statistical issues in the assessment of the evidence for an interaction between factors in epilepsy trials. Statistics in Medicine, 2002, 21, 2613-2622.	0.8	13
212	Tiagabine add-on for drug-resistant partial epilepsy. , 2012, , CD001908.		13
213	High mobility group box 1 in the inflammatory pathogenesis of epilepsy: profiling circulating levels after experimental and clinical seizures. Lancet, The, 2014, 383, S105.	6.3	13
214	Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population. Epilepsy and Behavior, 2014, 36, 12-17.	0.9	13
215	Pregabalin add-on for drug-resistant focal epilepsy. The Cochrane Library, 2019, 7, CD005612.	1.5	13
216	Antidepressants for people with epilepsy and depression. The Cochrane Library, 2021, 2021, CD010682.	1.5	13

#	Article	IF	Citations
217	A call from the European Academy of Neurology on COVID-19. Lancet Neurology, The, 2020, 19, 482.	4.9	13
218	Importance of competing risks in the analysis of anti-epileptic drug failure. Trials, 2007, 8, 12.	0.7	12
219	Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence. Epilepsy and Behavior, 2015, 45, 180-186.	0.9	12
220	Ketogenic diets as an adjuvant therapy in glioblastoma (the KEATING trial): study protocol for a randomised pilot study. Pilot and Feasibility Studies, 2017, 3, 67.	0.5	12
221	Genomic and clinical predictors of lacosamide response in refractory epilepsies. Epilepsia Open, 2019, 4, 563-571.	1.3	12
222	Antiepileptic drugs as prophylaxis for postcraniotomy seizures. The Cochrane Library, 2020, 4, CD007286.	1.5	12
223	Functional network topology in drug resistant and well-controlled idiopathic generalized epilepsy: a resting state functional MRI study. Brain Communications, 2021, 3, fcab196.	1.5	12
224	Fiber ball white matter modeling in focal epilepsy. Human Brain Mapping, 2021, 42, 2490-2507.	1.9	12
225	Diverse genetic causes of polymicrogyria with epilepsy. Epilepsia, 2021, 62, 973-983.	2.6	12
226	Evaluation of the 2020 European Academy of Neurology virtual congress: transition from a faceâ€toâ€face to a virtual meeting. European Journal of Neurology, 2021, 28, 2523-2532.	1.7	12
227	Altered Structural Brain Networks in Refractory and Nonrefractory Idiopathic Generalized Epilepsy. Brain Connectivity, 2022, 12, 549-560.	0.8	12
228	Comparing antiepileptic drugs. Current Opinion in Neurology, 1996, 9, 103-106.	1.8	11
229	Metaâ€regression with partial information on summary trial or patient characteristics. Statistics in Medicine, 2010, 29, 1312-1324.	0.8	11
230	Calcium antagonists as an add-on therapy for drug-resistant epilepsy. The Cochrane Library, 2013, , CD002750.	1.5	11
231	A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease. Biomarkers, 2016, 22, 1-8.	0.9	11
232	Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2016, 12, CD012065.	1.5	11
233	Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2016, 11, CD001031.	1.5	11
234	Paramedics' views on their seizure management learning needs: a qualitative study in England. BMJ Open, 2017, 7, e014024.	0.8	11

#	Article	IF	Citations
235	Rufinamide add-on therapy for refractory epilepsy. The Cochrane Library, 2018, 4, CD011772.	1.5	11
236	Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. British Journal of Clinical Pharmacology, 2021, 87, 2572-2588.	1.1	11
237	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 2019, 129, 2166-2166.	3.9	11
238	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Health Technology Assessment, 2021, 25, 1-134.	1.3	11
239	Sulthiame monotherapy for epilepsy. The Cochrane Library, 2014, , CD010062.	1.5	10
240	Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. , 2015, , CD001904.		10
241	Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. , 2015, , CD001911.		10
242	Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2019, 2019, CD001911.	1.5	10
243	Statins as antiepileptogenic drugs: Analyzing the evidence and identifying the most promising statin. Epilepsia, 2022, 63, 1889-1898.	2.6	10
244	Vagus nerve stimulation for focal seizures. The Cochrane Library, 2022, 2022, .	1.5	10
245	The Cochrane Collaboration: Systematic Reviews and Their Relevance to Epilepsy. Epilepsia, 1996, 37, 917-921.	2.6	9
246	Profound Amnesia after Temporal Lobectomy: An Autoimmune Process Resembling Patient H.M.. Case Reports in Neurology, 2014, 6, 251-255.	0.3	9
247	Hippocampal internal architecture and postoperative seizure outcome in temporal lobe epilepsy due to hippocampal sclerosis. Seizure: the Journal of the British Epilepsy Association, 2016, 35, 65-71.	0.9	9
248	Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2018, 2018, CD001904.	1.5	9
249	A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine. Epilepsia Open, 2019, 4, 102-109.	1.3	9
250	A multiorganism pipeline for antiseizure drug discovery: Identification of chlorothymol as a novel γ-aminobutyric acidergic anticonvulsant. Epilepsia, 2020, 61, 2106-2118.	2.6	9
251	Thalamohippocampal atrophy in focal epilepsy of unknown cause at the time of diagnosis. European Journal of Neurology, 2021, 28, 367-376.	1.7	9
252	Exploring the prevalence and profile of epilepsy across Europe using a standard retrospective chart review: Challenges and opportunities. Epilepsia, 2021, 62, 2651-2666.	2.6	9

#	Article	IF	Citations
253	The provision of epilepsy care across Europe 2017: A 17‑year follow‑up survey. Epilepsia Open, 2019, 4, 144-152.	1.3	9
254	Computed tomography in patients with epileptic seizures admitted acutely to hospital: A population level analysis of routinely collected healthcare data. Clinical Medicine, 2020, 20, 178-182.	0.8	9
255	Using common genetic variants to find drugs for common epilepsies. Brain Communications, 2021, 3, fcab287.	1.5	9
256	New Statistical Method for Analyzing Time to First Seizure: Example Using Data Comparing Carbamazepine and Valproate Monotherapy. Epilepsia, 2007, 48, 1173-1178.	2.6	8
257	Non-pharmacological interventions for people with epilepsy and intellectual disabilities. The Cochrane Library, 2015, 2015, CD005502.	1.5	8
258	Assessment of the quality of harms reporting in non-randomised studies and randomised controlled studies of topiramate for the treatment of epilepsy using CONSORT criteria. Epilepsy Research, 2015, 114, 106-113.	0.8	8
259	Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. The Cochrane Library, 2016, 4, CD001769.	1.5	8
260	Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. The Cochrane Library, 2017, 2017, CD007124.	1.5	8
261	Gabapentin add-on treatment for drug-resistant focal epilepsy. The Cochrane Library, 2018, 10, CD001415.	1.5	8
262	Nerve root block versus surgery (NERVES) for the treatment of radicular pain secondary to a prolapsed intervertebral disc herniation: study protocol for a multi-centre randomised controlled trial. Trials, 2018, 19, 475.	0.7	8
263	What really matters? A mixed methods study of treatment preferences and priorities among people with epilepsy in the UK. Epilepsy and Behavior, 2019, 95, 181-191.	0.9	8
264	Protocol for the development of a core outcome set for cauda equina syndrome: systematic literature review, qualitative interviews, Delphi survey and consensus meeting. BMJ Open, 2019, 9, e024002.	0.8	8
265	Developing patient-centred, feasible alternative care for adult emergency department users with epilepsy: protocol for the mixed-methods observational 'Collaborate' project. BMJ Open, 2019, 9, e031696.	0.8	8
266	Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2019, 2019, CD012065.	1.5	8
267	Tiagabine add-on therapy for drug-resistant focal epilepsy. The Cochrane Library, 2019, 2019, CD001908.	1.5	8
268	Neuroradiological findings in patients with "non-lesional" focal epilepsy revealed by research protocol. Clinical Radiology, 2019, 74, 78.e1-78.e11.	0.5	8
269	Association of ultra‑rare coding variants with genetic generalized epilepsy: A case–control whole exome sequencing study. Epilepsia, 2022, 63, 723-735.	2.6	8
270	Brivaracetam add-on therapy for drug-resistant epilepsy. The Cochrane Library, 2022, 2022, CD011501.	1.5	8

#	Article	IF	Citations
271	Calcium antagonists as an add-on therapy for drug-resistant epilepsy. , 2001, , CD002750.		7
272	Remacemide for drug-resistant localization related epilepsy. The Cochrane Library, 2002, , CD001900.	1.5	7
273	Immunomodulatory interventions for focal epilepsy syndromes. The Cochrane Library, 2013, , CD009945.	1.5	7
274	Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data. European Journal of Human Genetics, 2017, 25, 894-899.	1.4	7
275	Clobazam add-on therapy for drug-resistant epilepsy. The Cochrane Library, 2019, 2019, CD004154.	1.5	7
276	Vigabatrin add-on therapy for drug-resistant focal epilepsy. The Cochrane Library, 2020, 2020, CD007302.	1.5	7
277	Reducing variation in hospital mortality for alcohol€related liver disease in North West England. Alimentary Pharmacology and Therapeutics, 2020, 52, 182-195.	1.9	7
278	Levetiracetam add-on for drug-resistant focal epilepsy. The Cochrane Library, 2020, 2020, .	1.5	7
279	Care in Europe after presenting to the emergency department with a seizure; position paper and insights from the European Audit of Seizure Management in Hospitals. European Journal of Neurology, 2022, 29, 1873-1884.	1.7	7
280	Development of â€˜Core Outcome Setsâ€™ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings. BMJ Open, 2022, 12, e057384.	0.8	7
281	Efficacy of carbamazepine and valproate as monotherapy for early epilepsy and single seizures. Neurology, 2006, 67, 1872-1875.	1.5	6
282	Review: Comparing drug treatments in epilepsy. Therapeutic Advances in Neurological Disorders, 2009, 2, 181-187.	1.5	6
283	Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2016, 12, CD001904.	1.5	6
284	Developing and assessing the acceptability of an epilepsy first aid training intervention for patients who visit UK emergency departments: A multi-method study of patients and professionals. Epilepsy and Behavior, 2017, 68, 177-185.	0.9	6
285	Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2018, 2018, CD003615.	1.5	6
286	Perceptions of emergency care using a seizure care pathway for patients presenting to emergency departments in the North West of England following a seizure: a qualitative study. BMJ Open, 2018, 8, e021246.	0.8	6
287	Investigating imaging network markers of cognitive dysfunction and pharmacoresistance in newly diagnosed epilepsy: a protocol for an observational cohort study in the UK. BMJ Open, 2019, 9, e034347.	0.8	6
288	Sulthiame add-on therapy for epilepsy. The Cochrane Library, 2019, 2019, CD009472.	1.5	6

#	Article	IF	Citations
289	Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II). BMJ Open, 2020, 10, e040635.	0.8	6
290	Oxcarbazepine add-on for drug-resistant focal epilepsy. The Cochrane Library, 2020, 2020, CD012433.	1.5	6
291	Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. Frontiers in Pharmacology, 2021, 12, 688386.	1.6	6
292	Gabapentin add-on treatment for drug-resistant focal epilepsy. The Cochrane Library, 2021, 2021, CD001415.	1.5	6
293	Pregabalin add-on for drug-resistant focal epilepsy. The Cochrane Library, 2022, 2022, CD005612.	1.5	6
294	Reappraisal of the Medical Research Council Antiepileptic Drug Withdrawal Study: Contaminationâ€adjusted and doseâ€response reâ€analysis. Epilepsia, 2022, 63, 1724-1735.	2.6	6
295	Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. , 2010, , CD007124.		5
296	UK epilepsy audit shows major deficiencies in care: who should respond and how?. Practical Neurology, 2013, 13, 2-3.	0.5	5
297	A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine. Pharmacogenomics Journal, 2014, 14, 481-487.	0.9	5
298	Covalent adduction of carbamazepine 10, 11-epoxide with human serum albumin and glutathione S-transferase pi: implications for carbamazepine hypersensitivity. Lancet, The, 2014, 383, S114.	6.3	5
299	Sulthiame add-on therapy for epilepsy. The Cochrane Library, 2015, , CD009472.	1.5	5
300	Are â€œTheory of Mindâ€•Skills in People with Epilepsy Related to How Stigmatised They Feel? An Exploratory Study. Behavioural Neurology, 2016, 2016, 1-9.	1.1	5
301	Assessing Treatment Fidelity within an Epilepsy Randomized Controlled Trial: Seizure First Aid Training for People with Epilepsy Who Visit Emergency Departments. Behavioural Neurology, 2019, 2019, 1-11.	1.1	5
302	Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures. The Cochrane Library, 2020, 2020, CD007783.	1.5	5
303	Shared genetic basis between genetic generalized epilepsy and background electroencephalographic oscillations. Epilepsia, 2021, 62, 1518-1527.	2.6	5
304	Risk of seizure recurrence in people with single seizures and early epilepsy â€" Model development and external validation. Seizure: the Journal of the British Epilepsy Association, 2022, 94, 26-32.	0.9	5
305	Opportunities and challenges for the development of â€œcore outcome setsâ€•in neuro-oncology. Neuro-Oncology, 2022, 24, 1048-1055.	0.6	5
306	Letters to the Editor. Epilepsia, 1999, 40, 531-533.	2.6	4

#	ARTICLE	IF	CITATIONS
307	Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. The Cochrane Library, 2010, , CD007783.	1.5	4
308	An integrative *in silico* system for predicting dysregulated genes in the human epileptic focus: Application to SLC transporters. Epilepsia, 2016, 57, 1467-1474.	2.6	4
309	Testing HLA-B*15:02. Neurology, 2016, 86, 1080-1081.	1.5	4
310	Identifying patients who will not reachieve remission after breakthrough seizures. Epilepsia, 2019, 60, 774-782.	2.6	4
311	Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review. The Cochrane Library, 2019, 7, CD002217.	1.5	4
312	Rufinamide add-on therapy for drug-resistant epilepsy. The Cochrane Library, 2020, 11, CD011772.	1.5	4
313	Autoimmune encephalitis as an increasingly recognised cause of non-convulsive status epilepticus: A retrospective, multicentre evaluation of patient characteristics and electroencephalography (EEG) results. Seizure: the Journal of the British Epilepsy Association, 2020, 80, 153-156.	0.9	4
314	Clinically unnecessary and avoidable emergency health service use for epilepsy: A survey of what English services are doing to reduce it. Seizure: the Journal of the British Epilepsy Association, 2020, 76, 156-160.	0.9	4
315	Microdiscectomy compared with transforaminal epidural steroid injection for persistent radicular pain caused by prolapsed intervertebral disc: the NERVES RCT. Health Technology Assessment, 2021, 25, 1-86.	1.3	4
316	Using routinely recorded data in a UK RCT: a comparison to standard prospective data collection methods. Trials, 2021, 22, 429.	0.7	4
317	Large pragmatic randomised studies of new antiepileptic drugs are needed. BMJ: British Medical Journal, 1997, 314, 1764-1764.	2.4	4
318	High b-value diffusion tractography: Abnormal axonal network organization associated with medication-refractory epilepsy. NeuroImage, 2022, 248, 118866.	2.1	4
319	Old versus new antiepileptic drugs: the SANAD study – Authors' reply. Lancet, The, 2007, 370, 315-316.	6.3	3
320	Sulthiame add-on therapy for epilepsy. , 2013, , CD009472.		3
321	Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. , 2014, , CD007124.		3
322	Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. The Cochrane Library, 2021, 2021, CD007144.	1.5	3
323	Approach to the Medical Treatment of Epilepsy. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 483-499.	0.4	3
324	Assessing the risk of subsequent tonic–clonic seizures in patients with a history of simple or complex partial seizures. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 803-809.	0.9	2

#	ARTICLE	IF	CITATIONS
325	Rufinamide add-on therapy for refractory epilepsy. The Cochrane Library, 2015, , .	1.5	2
326	Oxcarbazepine add-on for drug-resistant partial epilepsy. The Cochrane Library, 2016, , .	1.5	2
327	Psychological interventions for epilepsy: How good are trialists at assessing their implementation fidelity, what are the barriers, and what are journals doing to encourage it? A mixed methods study. Epilepsy and Behavior, 2019, 97, 174-181.	0.9	2
328	Pharmacotherapy for Medication-Resistant Epilepsy. , 2020, , 179-186.		2
329	EAN congress highlights challenges â€" predict, prevent, repair. Nature Reviews Neurology, 2020, 16, 401-402.	4.9	2
330	A quantitative framework to inform extrapolation decisions in children. Journal of the Royal Statistical Society Series A: Statistics in Society, 2020, 183, 515-534.	0.6	2
331	Prognosis of adults and children following a first unprovoked seizure. The Cochrane Library, 0, , .	1.5	2
332	What is the optimal management of partial epilepsy uncontrolled by a first choice anticonvulsant?. BMJ: British Medical Journal, 2008, 337, a2199-a2199.	2.4	2
333	Seizure first aid training for people with epilepsy attending emergency departments and their significant others: the SAFE intervention and feasibility RCT. Health Services and Delivery Research, 2020, 8, 1-190.	1.4	2
334	Epilepsy (partial). Clinical Evidence, 2011, 2011, .	0.2	2
335	Epileptic Seizures in Alzheimerâ€™s Disease: What Are the Implications of SANAD II?. Journal of Alzheimer's Disease, 2022, 85, 527-529.	1.2	2
336	Socioeconomic and health factors related to polypharmacy and medication management: analysis of a Household Health Survey in North West Coast England. BMJ Open, 2022, 12, e054584.	0.8	2
337	Anti-epileptic drug harms: issues for meta-analysis. Trials, 2011, 12, .	0.7	1
338	New advice on switching antiepileptic drugs might be a false economy. BMJ, The, 2013, 347, f7471-f7471.	3.0	1
339	Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. , 2014, , CD007124.		1
340	Preconception counselling for women with epilepsy. The Cochrane Library, 2014, , .	1.5	1
341	Presurgical entorhinal cortex volume and postoperative seizure outcome in temporal lobe epilepsy. Lancet, The, 2015, 385, S34.	6.3	1
342	A disease, disorder, illness or condition: How to label epilepsy?. Acta Neurologica Scandinavica, 2017, 136, 536-540.	1.0	1

#	Article	IF	Citations
343	Seizure First Aid Training For people with Epilepsy (SAFE) frequently attending emergency departments and their significant others: results of a UK multi-centre randomised controlled pilot trial. BMJ Open, 2020, 10, e035516.	0.8	1
344	Modelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs. BMC Medical Research Methodology, 2020, 20, 84.	1.4	1
345	Prognostic factors predicting an unprovoked seizure recurrence in children and adults following a first unprovoked seizure. The Cochrane Library, 0, , .	1.5	1
346	Antiepileptic drug add-on therapy for focal epilepsy: a network meta-analysis. The Cochrane Library, 0, , .	1.5	1
347	Sulthiame monotherapy for epilepsy. The Cochrane Library, 2021, 2021, CD010062.	1.5	1
348	Epilepsy (generalised). Clinical Evidence, 2012, 2012, .	0.2	1
349	Worth the paper they're printed on? Findings from an independent evaluation of how understandable patient information leaflets for antiseizure medications are. Epilepsia, 2022, , .	2.6	1
350	Using discrete choice experiments to define patient preferences for outcomes in trials. Trials, 2013, 14, .	0.7	0
351	External validation of a prognostic index. Trials, 2013, 14, .	0.7	0
352	HIPPOCAMPAL INTERNAL ARCHITECTURE AND POSTOPERATIVE OUTCOME IN TEMPORAL LOBE EPILEPSY. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.147-e4.	0.9	0
353	PO039â€¦Gwas for early remission in newly diagnosed focal epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A22.1-A22.	0.9	0
354	Maternal Use of Antiepileptic Agents During Pregnancy and Major Congenital Malformations in Children. Obstetrical and Gynecological Survey, 2018, 73, 139-140.	0.2	0
355	SEIZURE PROPHYLAXIS IN GLIOMA - UK NEUROSURGICAL SURVEY AND CLINICAL TRIAL. Neuro-Oncology, 2018, 20, v354-v354.	0.6	0
356	Quantitative analysis of phenotypic elements augments traditional electroclinical classification of common familial epilepsies. Epilepsia, 2019, 60, 2194-2203.	2.6	0
357	Preconception care for women with epilepsy: a mixed methods review. The Cochrane Library, 2020, , .	1.5	0
358	C. elegans as a Potential Model for Acute Seizure-Like Activity. Neuromethods, 2021, , 233-248.	0.2	0
359	Retigabine add-on for refractory partial-onset seizures. The Cochrane Library, 2021, 2021, .	1.5	0
360	Valproate add-on therapy for drug-resistant focal epilepsy. The Cochrane Library, 2021, 2021, .	1.5	0

#	Article	IF	Citations
361	Care After Presenting with Seizures (CAPS): An analysis of the impact of a seizure referral pathway and nurse support on neurology referral rates for patients admitted with a seizure. Seizure: the Journal of the British Epilepsy Association, 2021, 92, 18-23.	0.9	0
362	Automated subcortical volume estimation from 2D MRI in epilepsy and implications for clinical trials. Neuroradiology, 2021, , 1.	1.1	0
363	Does Early Treatment Influence the Long-Term Outcome of Epilepsy?. Blue Books of Neurology, 2009, , 265-276.	0.1	0
364	A Randomised Controlled Trial of Surgical Microdiscectomy Versus Trans-Foraminal Epidural Steroid Injection for Sciatica of Up to 1 Year; The NERVES Trial. SSRN Electronic Journal, 0, , .	0.4	0
365	Epilepsy (generalised). Clinical Evidence, 2010, 2010, .	0.2	0
366	The importance of getting evidence into practice. Nature Reviews Neurology, 0, , .	4.9	0